In direct compression lines processing calcium citrate tetrahydrate at elemental calcium loadings above 500 mg per tablet, the powder blend is transferred through a bin blender at 60–70% vessel fill and discharged through a rotary tablet press equipped with a 16–20 station turret and forced feeder. Calcium citrate tetrahydrate contributes approximately 21% elemental calcium on an as-is basis, so a 500 mg elemental calcium dose requires approximately 2,380 mg of the tetrahydrate API, which produces a large oblong tablet. Direct compression is commercially feasible only when the API is co-processed with plastic-deforming fillers such as microcrystalline cellulose and with a disintegrant such as croscarmellose sodium at 2.0–5.0% w/w. The brittle fragmentation of calcium citrate tetrahydrate under main compression stress increases surface area and can cause punch filming; precompression at 8–12 kN on a 16 mm round tooling set reduces capping and lowers ejection force. Magnesium stearate is incorporated at 0.75–1.0% w/w through a 40-mesh screen and blended for not more than 3 min after the main blend has reached homogeneity confirmed by blend uniformity sampling per USP <905>. Over-lubrication beyond 5 min produces a hydrophobic coat on the particles and a measurable loss of tablet tensile strength at the same compaction force. The finished tablet hardness is maintained between 80 N and 120 N when measured on a Schleuniger hardness tester, but the upper limit is constrained by USP <701> disintegration; tablets above 120 N frequently show disintegration times exceeding 30 min in water at 37 °C. Dissolution testing uses USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid, with sampling at 15, 30, and 45 min; calcium citrate dissolves rapidly in acidic medium because the citrate ion becomes protonated and free calcium ion is released. Bulk density measurements per USP <616> should be performed on each incoming lot because a shift from 0.45 g/mL to 0.60 g/mL can alter die fill and tablet weight variation.

Lot-to-lot variation in calcium citrate tetrahydrate crystallised from different suppliers affects direct compression. When the powder bed is sampled during compression with USP <616> Method I, bulk density values below 0.45 g/mL are associated with die fill inconsistency and tablet weight variation above 2%. Batch records from production-scale rotary presses show that a forced feeder speed above 60 rpm can induce overfeeding in low-bulk-density powder and cause punch binding. To control this, the feeder speed is set to 25–40 rpm and the turret speed is limited to 20–40 rpm depending on tooling diameter. The use of 0.5% w/w colloidal silicon dioxide reduces bulk density variation but can extend disintegration time by 2–4 min at levels above 0.5% w/w. Tablets formulated with 2.0–5.0% w/w croscarmellose sodium and compressed at 80–120 N hardness generally meet a disintegration limit of not more than 30 min under USP <701>, but the dissolution profile shifts when the formulation contains calcium carbonate as an alkalizer.

Why Does Low-Tap-Density Calcium Citrate Require Slugging Before Two-Piece Capsule Filling?

Two-piece hard gelatin and HPMC capsule lines using dosator filling heads require a powder bed with sufficient bulk density and flow to maintain weight variation below ±3% across a 10,000 capsule batch. Calcium citrate tetrahydrate from crystallisation is characterised by a low tap density and a cohesive fines fraction; when loaded directly into a dosator capsule filling machine at speeds above 30,000 capsules/h, the powder compresses in the dosator tube and forms a compacted plug that may not eject cleanly. Slugging on a rotary tablet press with 20 mm flat-faced tooling at 10–20 kN improves bulk density to approximately 0.65–0.75 g/mL and creates slugs that are screened through an 18-mesh stainless steel sieve. Roller compaction is preferred for continuous lines, with roll gap set at 1.0–2.0 mm and granulate screened to D50 300–500 µm. The resulting granulate is filled into size 00 or size 000 capsules to deliver 250–500 mg elemental calcium per unit. For HPMC capsules with moisture content below 3% at equilibrium, the hydrate water of calcium citrate tetrahydrate has not been observed to cause brittleness at 40 °C/75% RH storage in typical stability protocols. Capsule fill weight is checked by in-process sampling every 15 min and compared against the target using a precision balance; the acceptance limit is ±5% of target fill weight in early development and tightened to ±2% at commercial registration.

The hydration state of the API is assessed by loss on drying because over-drying converts the tetrahydrate to an anhydrous or amorphous form and changes the elemental calcium calculation per unit fill. A production-scale failure mode occurs when dry granulate is exposed to room conditions above 60% RH; the fines adsorb surface water and the powder flow time through a 15 mm orifice increases from 10 s to more than 30 s for a 100 g sample. In such lots, capsules are filled below target and the content uniformity tested by USP <905> may fail because the dosator does not fully charge at each cycle. Preconditioning of the granulate in a dehumidified room at 30–35% RH for 24 h restores acceptable flow, but the line must be monitored for moisture regain during extended running.

Because effervescent granulation is sensitive to free water, the binder solution for calcium citrate tetrahydrate effervescent formulations is prepared in anhydrous ethanol rather than purified water. The dry powder charge contains calcium citrate tetrahydrate, anhydrous citric acid, and sodium bicarbonate at a bicarbonate-to-citric-acid molar ratio not less than 3:1, with sodium carbonate or sodium sesquicarbonate added only when a slower gas release is required. A binder solution of 5% PVP K30 in anhydrous ethanol is sprayed at inlet air temperature 45–55 °C and product temperature 32–38 °C; spray rate is adjusted to 8–12 g/min per kg of dry blend to prevent overwetting. The granulate is dried until free moisture is below 0.5% w/w by Karl Fischer method, using an oven method that does not strip the four water molecules of calcium citrate tetrahydrate. Residual solvents are controlled under ICH Q3C for Class 3 ethanol, and a final residual ethanol limit of 5000 ppm is routinely applied. When the effervescent product is reconstituted in 200 mL of water at 20–25 °C, the citric acid protonates the citrate ligand of the calcium salt, producing soluble calcium citrate species and free calcium ion within 3–5 min; the pH of the solution falls from near neutral to 3.5–4.5, which is sufficient for complete dissolution. The gas release rate is measured by carbon dioxide evolution and is specified as not less than 90% of theoretical within 5 min. An uncoated effervescent tablet with calcium citrate tetrahydrate is sensitive to moisture ingress, so primary packaging uses aluminium foil with desiccant; hot-sealed PVC/PVDC blisters are not used.

Processing conflict arises when residual alcohol is removed too quickly at product temperature above 50 °C; this softens the PVP binder and causes agglomerate collapse. The gas-release kinetics are measured by a graduated gas burette; tablets are dropped into 200 mL of deionized water at 25 °C, and the volume of CO₂ released is recorded at 2, 5, and 10 min. A release below 85% of theoretical at 5 min indicates incomplete wetting, often caused by hydrophobic magnesium stearate migration from the tooling surface into the granulate. Magnesium stearate is therefore limited to 0.5% w/w in effervescent calcium citrate tablet formulas and is added after the granulation step.

When Calcium Citrate Replaces Calcium Carbonate in Chewable Tablets, What Changes in Binder Compatibility?

Chewable tablet formulations using calcium citrate tetrahydrate are processed in high-shear mixers at impeller speed 300 rpm and chopper speed 1500 rpm; the binder solution is added at 8–12% of dry powder weight. Calcium citrate does not produce carbon dioxide on contact with gastric acid, unlike calcium carbonate, so the organoleptic profile is less chalky but still astringent due to the citrate anion. Binder selection shifts from starch paste to plasticizing binders such as copovidone or maltitol syrup because the high solubility of calcium citrate in acidic mouth pH can expose crystalline fines on the tablet surface during mastication. The wet mass is granulated to an endpoint torque of 100–120 N·m on a mixer with a 25 L bowl and then dried in a fluid-bed dryer at 45–55 °C until loss on drying is 0.5–2.0% w/w above the theoretical hydrate water. Taste masking is achieved with 0.1–0.3% sodium saccharin, 0.2–0.5% citric acid, and 1.0–2.0% mint flavour; the added citric acid does not significantly alter the total citrate content because the API already contributes citrate. Tablet hardness is set lower than that of swallow tablets, at 40–70 N, to allow comfortable chewing without excessive tooth pack. The main incompatibility in chewable systems is with hygroscopic sweeteners; sorbitol above 5% w/w can increase moisture uptake and cause surface spotting in aluminium blister packaging.

Organoleptic failure in chewable tablets is traced to the astringent calcium-citrate complex that forms at the tooth surface. The addition of 1.0–2.0% w/w peppermint oil in a spray-dried flavour carrier masks the initial astringency but does not eliminate the aftertaste. Chewable tablets are compressed at lower forces because high compression above 70 N reduces the rate of saliva penetration and increases the perceived chalkiness during chewing. Friability is controlled by USP <1216> if the tablet is scored; the test is performed on 10 tablets for 4 min at 25 rpm. A friability loss not more than 1.0% is considered acceptable for this dosage form.

Oral Suspension Rheology and Sedimentation Control for Calcium Citrate Tetrahydrate

Oral suspension batches of calcium citrate tetrahydrate are not true solutions; the API remains suspended as particles, and the formulation must be designed for dose uniformity under shaking. Wet milling in a high-shear rotor-stator mill reduces the D90 to below 20 µm, which increases the specific surface area and raises the dissolution rate in gastric fluid. The suspending vehicle is prepared with microcrystalline cellulose and sodium carboxymethylcellulose at 0.4–0.6% w/v, xanthan gum at 0.2–0.4% w/v, and sorbitol solution as a sweetening and density-modifying agent. The target viscosity is 300–800 mPa·s at 25 °C on a Brookfield viscometer using spindle 2 at 30 rpm; lower viscosity permits rapid sedimentation, while higher viscosity causes poor pourability and incomplete rinsing from the dosing cup. The sedimentation volume after 24 h should be not less than 0.9; resuspendability is checked by shaking for 15 s and sampling for content uniformity per USP <905>. At pH 6.0–6.5, the zeta potential of the calcium citrate particles is close to zero, so flocculation can occur unless a citrate buffer or sodium citrate is added at 0.1–0.3% w/v; sodium citrate also suppresses crystal growth by increasing the aqueous citrate ligand concentration. A unit-dose sachet containing dry powder for reconstitution is often preferred over multi-dose suspension because the dry blend can be filled at moisture below 0.5% free water and avoids preservative challenge testing. If a clear oral solution is required, calcium citrate is not suitable; the solubility boundary below 1 g/L at 25 °C means a 5 mL dose would contain less than 5 mg of API.

When the suspension is stored at 40 °C/75% RH in accelerated stability, the main physicochemical change is a slight downward pH drift from 6.5 to 6.0 due to citric acid dissociation; viscosity may fall by 10–15% if xanthan gum is not fully hydrated at the initial mixing step. The suspended particles should be assessed by laser diffraction for D50 before and after storage; an increase in D50 from 15 µm to 30 µm indicates crystal growth, which can be suppressed by the addition of sodium citrate. Preservative efficacy testing per USP <51> is required only for multi-dose oral suspension containers; unit-dose sachets avoid this test.

Injection-Solution Screening and Solubility-Limited Excipient Selection

Injectable formulation screening for calcium citrate is constrained at the solubility boundary rather than by chemical compatibility. Calcium citrate tetrahydrate has an aqueous solubility below 1 g/L at 25 °C, and the saturated solution remains turbid at pH values above 6.0 because citrate ion binds calcium in a sparingly soluble network. A 10 mL unit for intravenous administration could deliver less than 10 mg of calcium citrate under saturated conditions, which is inadequate when compared with the elemental calcium concentration of 9.3 mg/mL in 10% calcium gluconate injection; calcium gluconate and calcium chloride remain the recognized parenteral calcium salts. Sterile filtration of a suspended calcium citrate formulation through a 0.22 µm membrane is not feasible for a traditional solution because the API content would be retained; terminal sterilization by autoclaving would cause thermal degradation of citrate and pH drift. The pH range acceptable for intravenous administration is 5.5–8.5, and calcium citrate solubility does not increase sufficiently within that range to support a therapeutically useful dose. The only injectable pathway that could be explored is a sterile suspension for intramuscular or subcutaneous depot injection, but published data for this specific configuration is limited, and the particle size would need to be controlled under 10 µm with a narrow span to avoid capillary blockage. For oral and enteral formulations, the low aqueous solubility is less limiting because gastric acid provides a pH 1.2–2.0 environment that protonates citrate and releases calcium ion; this is the basis for the oral dosage forms described above. No USP monograph exists for calcium citrate injection, and injectable formulation development should not proceed without a pre-IND solubility enhancement strategy backed by particle engineering data.